Delving into the Latest Updates on Teniposide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4'-demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside), ETP, Epidophyllotoxin

+ [6]

Target

Top II

Action

inhibitors

Mechanism

Top II inhibitors(Topoisomerase II inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [3]

Active Indication

Acute Lymphoblastic LeukemiaAstrocytomaBladder Cancer+ [3]

Inactive Indication-

Originator Organization

HQ Specialty Pharma Corp.

Active Organization

China Resources Double-Crane Pharmaceutical Co., Ltd.

Inactive Organization

HQ Specialty Pharma

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (14 Jul 1992),

Acute Lymphoblastic Leukemia

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC32H32O13S

InChIKeyNRUKOCRGYNPUPR-QBPJDGROSA-N

CAS Registry29767-20-2

The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.

Start Date07 Jan 2025

Sponsor / Collaborator

Shanghai Pulmonary Hospital

[+1]

ChiCTR2400087032

/ SuspendedPhase 4IIT

A single-center, prospective, open, single-arm, phase II clinical study exploring the efficacy and safety of injectable teniposide combined with temozolomide in recurrent high-grade gliomas

Start Date22 Jul 2024

Sponsor / Collaborator-

100 Clinical Results associated with Teniposide

Login to view more data

100 Translational Medicine associated with Teniposide

Login to view more data

100 Patents (Medical) associated with Teniposide

Login to view more data

2,407

Literatures (Medical) associated with Teniposide

01 Jun 2025·Neurobiology of Disease

Differences in transcriptome characteristics and drug repositioning of Alzheimer's disease according to sex

Article

Author: Hu, Yazhuo ; Sun, Xuan ; Ye, Ling ; Chen, Siyu ; Liu, Jing ; Fan, Jiao ; Jia, Jianjun ; Li, Ke ; Shi, Jingqi ; Liu, Jianwei ; Zhang, Minghua

BACKGROUNDPrevious studies have shown significant sex differences in AD with regarding its epidemiology, pathophysiology, clinical presentation, and treatment response. However, the transcriptome variances associated with sex in AD remain unclear.METHODSRNA sequencing (RNA-seq) and transcriptomic analyses were performed on peripheral blood samples from total of 54 patients, including male AD patients (n = 15), female AD patients (n = 10), male MCI patients (n = 7), female MCI patients (n = 11), male healthy controls (n = 6), female healthy controls (n = 5). The snRNA-seq dataset (GSE167494, GSE157827) of prefrontal cortex tissues was obtained from the Gene Expression Omnibus (GEO). We conducted an investigation into differentially expressed genes and pathways in the peripheral blood cells as well as prefrontal cortex tissues of both male and female AD patients with consideration to sex-related factors. Additionally, we analyzed the distribution and characteristics of cells in the cerebral cortex as well as the interaction and communication between cells of male and female AD patients. Connectivity Map (CMap) was utilized for predicting and screening potential sex-specific drugs for AD.RESULTSThe transcriptome profile and associated biological processes in the peripheral blood of male and female AD and MCI patients exhibit discernible differences, including upregulation of BASP1 in AD male patients and arousing TNS1 in AD female patients. The distribution of various cell types in the prefrontal cortex tissues differs between male and female AD patients, like neuron and oligodendrocyte decreased and endothelial cell and astrocyte increased in female compared with male, while a multitude of genes exhibit significant differential expression. The results of cell communication analysis, such as collagen signaling pathway, suggest that sex disparities impact intercellular interactions within prefrontal cortex tissues among individuals with AD. By drug repositioning, several drugs, including torin-2 and YM-298198, might have the potential to therapeutic value of MCI or AD, while drugs like homoharringtonine and teniposide have potential opposite effects in different sexes.CONCLUSIONThe characteristics of the transcriptome in peripheral blood and single-cell transcriptome in the prefrontal cortex exhibit significant differences between male and female patients with AD, which providing a basis for future sex stratified treatment of AD.

01 Jun 2025·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors

Article

Author: Zhang, Xiaonan ; Rameika, Natallia ; Rendo, Verónica ; Stoimenov, Ivaylo ; Tsiara, Ioanna ; Kundu, Snehangshu ; Haberek, Wawrzyniec ; Globisch, Daniel ; Correia, Mario S P ; Sjöblom, Tobias

The Arylamine-N-acetyltransferase-2 (NAT2) enzyme is involved in metabolism of commonly used drugs driving differences in efficacy and tolerability of treatments. To bridge the current knowledge gap on metabolism of cytotoxic drugs by NAT2, and identify anticancer agents whose effects depend on NAT2 activity, we assessed 147 clinically used drugs. Hit compounds were evaluated for metabolic conversion by acetylation in presence of recombinant NAT2. Among those 147 drugs we found doxorubicin, daunorubicin, epirubicin, valrubicin, teniposide, afatinib, carmustine, vincristine, panobinostat, and vorinostat to have increased toxicity to cancer cells expressing the rapid NAT2 allele. Additionally, we report NAT2-mediated acetylation of idarubicin, daunorubicin, doxorubicin, vorinostat, and CUDC-101. These findings have implications for pharmacogenomics and cancer precision medicine using conventional chemotherapeutic drugs, as improving their efficacy and safety may affect >4 million cancer patients worldwide that receive these drugs as standard of care.

01 Apr 2025·Chemistry & Biodiversity

Plant Origin Source, Content Profile and Bioactivity of Podophyllotoxin as an Important Natural Anticancer Agent

Review

Author: Zhao, Dan ; Wang, Zhihao ; Duan, Kai ; Liu, Wei ; Yin, Dongxue

ABSTRACTPharmacological studies have shown that podophyllotoxin (PTOX) has anti‐tumor, antiviral, and anti‐inflammatory effects. More and more derivatives of PTOX, such as VM‐26, NK‐611 and GL‐331, have gradually been synthesized and are widely used in clinical practice. Sinopodophyllum hexandrum rhizome is rich in PTOX, which is much higher than other PTOX source plants. At present, research on S. hexandrum mainly focuses on artificial cultivation, chemical composition, pharmaceutical value, and the biosynthesis pathway of PTOX. However, the researches are relatively scattered, and systematic review on PTOX is very limited. Therefore, this study performed a comprehensive investigation of the plant origin source, content profile, and biological activities to provide an integrated reference for in‐depth research and clinical application of PTOX in the fields of chemistry and pharmacy, which can promote the innovative use of S. hexandrum resources and research and development of new anticancer drugs.

100 Deals associated with Teniposide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02698	Teniposide	L01CB02	DB00444

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1999
Astrocytoma	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1999
Bladder Cancer	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1999
Glioma	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1999
Lymphoma	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1999
Neuroblastoma	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1999

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01960192 (Pubmed \| J Neurooncol) Manual	Phase 2	Primary Central Nervous System Lymphoma BCL6 Overexpression	49	Fotemustine+teniposide+dexamethasone	(haeeheulpb) = saecbqvcbg qiefqlxbla (jrpveoovfj ) View more	Positive	01 Nov 2018
NCT01960192 (Pubmed \| J Neurooncol) Manual	Phase 2	Primary Central Nervous System Lymphoma BCL6 Overexpression	49	methotrexate+cytarabine	(haeeheulpb) = hmburpbgaz qiefqlxbla (jrpveoovfj ) View more	Positive	01 Nov 2018
ASCO2004	Phase 2	metastatic non-small cell lung cancer	-	Concurrent chemotherapy (teniposide and carboplatin) combined with whole brain radiotherapy	guykxglfzb(qpegkvckdi) = neutropoenia, thromocytopoenia, anaemia xhwmrpisjj (ojloumskat )	-	15 Jul 2004